Recently, the European Medicines Agency (EMA) approved marketing authorization for Lecanemab in patients with mild cognitive impairment and mild dementia due to AD, except for APOE-ε4 homozygotes due to increased risk of Amyloid Related Imaging Abnormalities (ARIA) [49]. This evidence concerns the gene APOE and Cognitive impairment.